Prostate Cancer International is
for 2011 by Great NonProfits
The recent publication of an article on trends in the prescription of finasteride has re-stimulated the debate on the use of 5α-reductase inhibitors (5-ARIs) like finasteride and dutasteride in the prevention of prostate cancer.
Filed under: Management, Prevention | Tagged: 5-ARIs, dutasteride, finasteride, Prevention | 2 Comments »
Earlier today, GlaxoSmithKline received approval from the US Food & Drug Administration to market Jalyn® — a fixed dose combination of dutasteride (Avodart) with tamulosin (Flomax) — for the treatment of benign prostatic hyperplasia (BPH).
Filed under: Diagnosis, Risk | Tagged: dutasteride, Jalyn | 2 Comments »
There are a couple of interesting new commentaries that discuss the idea of using 5α-reductase inhibitors to prevent prostate cancer (and other agents to prevent breast cancer).
Filed under: Prevention | Tagged: dutasteride, finasteride, Prevention | 1 Comment »
The final report from the REDUCE trial was published this morning in the New England Journal of Medicine. Most of these data were initially presented last year at the annual meeting of the American Urological Association (as reported at the time). However, there are two small problems.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: dutasteride, Prevention, risk | 2 Comments »
According to a media release earlier today, GlaxoSmithKline (GSK) has resubmitted data to the U.S. Food and Drug Administration (FDA) in support of the approval to market dutasteride (Avodart) as a drug to reduce the risk for prostate cancer among men believed to be at high risk.
Filed under: Prevention, Risk | Tagged: dutasteride, Prevention, risk | 1 Comment »
The “New” Prostate Cancer InfoLink has long argued that the potential of 5α-reductase inhibition (using finasteride and dutasteride) to prevent prostate cancer is under-appreciated and under-utilized. However, we also acknowledge a lack of good data to identify those patients for whom the benefits of prevention may outweigh the risks associated with the side effects of such treatment.
Filed under: Management, Prevention | Tagged: 5α-reductase inhibitor, dutasteride, finasteride, Prevention | 2 Comments »
Several experts discussed current issues related to prostate cancer prevention at the annual winter meeting of the Society for Urologic Oncology in Bethesda, MD, this week.
Filed under: Diagnosis, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention | 1 Comment »
There have been several reports in the past few days that GlaxoSmithKline (GSK) has withdrawn its supplemental New Drug Application (sNDA) for approval to market dutasteride (Avodart) in the US for the prevention of prostate cancer, based on the results from the REDUCE trial, announced earlier this year.
Filed under: Prevention | Tagged: dutasteride, Prevention, REDUCE trial | Leave a Comment »
The evidence supporting a role for the combination of dutasteride with ketoconazole as a form of second- or third-line hormone therapy for patients with castration-resistant prostate cancer (CRPC) appears to be increasing.
Filed under: Management, Treatment, Uncategorized | Tagged: castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole | 1 Comment »
In today’s news reports from sources other than the ASTRO meeting, we note items dealing with: PSA bounce in brachytherapy patients Fatal prostate cancer and a history of smoking Ketoconazole + dutasteride in treatment of CRPC
Filed under: Management, Prevention, Risk, Treatment | Tagged: Avodart, brachytherapy, castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole, PSA bounce, smoking | 1 Comment »
A number of physicians and patients have believed for years that so-called “triple” androgen blockade (ADT3) is a more effective option than an LHRH alone or combined androgen deprivation in the treatment of men with advanced prostate cancer. However, the clinical evidence supporting this belief has been limited.
Filed under: Management, Treatment | Tagged: ADT3, bicalutamide, dutasteride, TARP | 4 Comments »
Today’s news items deal with: The effect of dutasteride on the results of PCA3 tests How common is the TMPRSS2 fusion gene in men with prostate cancer in North America? Can prostate biopsy data predict laterality of prostate cancer with accuracy?
Filed under: Diagnosis, Risk, Uncategorized | Tagged: biopsy, dutasteride, ERG, laterality, PCA3, TMPRSS2 | 7 Comments »
Today’s news reports deal with: Diabetes, PSA, and prostate cancer risk Magnetic resonance spectroscopic imaging Ongoing trials of dutasteride as early stage treatment for prostate cancer
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: ARTS, diabetes, dutasteride, magmentic resonance spectroscopic imaging, MSRI, REDEEM, risk | Leave a Comment »
So Dr Gerry Andriole just completed his presentation of the main results of the REDUCE trial, designed to test the ability of dutasteride (Avodart) to prevent prostate cancer in men believed to be at high risk for this disease — and the results are positive.
Filed under: Diagnosis, Prevention, Risk | Tagged: dutasteride, Prevention, REDUCE | Leave a Comment »
According to a Reuters story earlier today, the results of the 8,000-patient REDUCE trial of dutasteride (Avodart) in prevention of prostate cancer will be presented on April 27 at the annual meeting of the American Urological Association.
Filed under: Diagnosis, Prevention, Risk | Tagged: dutasteride, Prevention, REDUCE trial | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site